HMGB1 and epilepsy: The extensively used HMGB1 targeting strategy against epilepsy is anti-HMGB1 monoclonal antibody (mAb) (Fu et al., 2017; Zhao et al., 2017) and Glycyrrhizin (natural inhibitor of HMGB1) (Luo et al., 2014; González-Reyes et al., 2016; Li et al., 2019).